Recently, Colortech Biotechnology, a company in SIP, officially launched its latest single-molecule immunoassay platform, FLAME, which represents a key technological breakthrough in the field of ultra-sensitive protein detection.

Colortech Biotechnology has moved beyond conventional designs by adopting the signal amplification technology. This allows signal molecule detection to no longer be constrained by physical structures like micropore or electrode arrays, thereby enabling free reaction and signal amplification in solution. As a result, the platform has achieved positive advances in sensitivity, throughput flexibility, and operational convenience.

The platform is expected to facilitate ultra-early screening and treatment monitoring for major diseases such as Alzheimer’s disease, cardiovascular disease, and cancer. It will also provide a highly sensitive, multi-marker parallel analysis solution for biomarker discovery and efficacy evaluation.

Moreover, FLAME is expected to drive the development of domestically produced core components, including optics, microfluidics, and reagents, thereby enhancing China’s self-sufficiency and control over high-end life science instruments.

April 9, 2026